Trial Profile
PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Fluorine-18 PSMA 1007 (Primary) ; Gallium (68Ga) gozetotide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Diagnostic use
- 13 Mar 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 13 Mar 2023 Planned primary completion date changed from 3 Feb 2023 to 3 Feb 2024.
- 08 Apr 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.